Polymeric micelles as potent islet amyloid inhibitors: Current advances and future perspectives

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Endocrinology

Background:

• Diabetes mellitus (DM) is a global health concern, often linked to pancreatic beta cell damage.
• Current treatments fail to address the root cause of DM, such as islet amyloid polypeptide (IAPP) misfolding.
• IAPP misfolding, implicated in over 90% of DM cases, stems from oxidative stress or genetic mutations.

Purpose of the Study:

• To review advancements in designing polymeric micelles (PMs) for halting islet amyloidosis.
• To elucidate the mechanisms and dynamics of PM-IAPP interactions.
• To identify clinical challenges in translating PMs as anti-islet amyloidogenic therapies.

Main Methods:

• Review of literature on polymeric micelle design for amyloidosis.
• Analysis of studies on PM-IAPP interaction mechanisms.
• Discussion of clinical trial data and regulatory hurdles for PM-based DM therapies.

Main Results:

• Polymeric micelles demonstrate potential in targeting and preventing IAPP misfolding.
• Understanding PM-IAPP dynamics is crucial for therapeutic efficacy.
• Significant clinical and regulatory challenges impede the translation of PMs into clinical practice.

Conclusions:

• Polymeric micelles represent a promising therapeutic strategy for diabetes by targeting islet amyloidosis.
• Further research into PM-IAPP interactions and robust clinical trials are necessary.
• Overcoming translational challenges is key to realizing the potential of PMs for diabetes treatment.